Viral Vector Manufacturing Market to hit US$ 3.8 billion by 2031 | Keyplayers - Sanofi SA, Thermo Fisher Scientific Inc., Cobra Biologics Ltd, Lonza Group Ltd, Merck & Co.

"Viral Vector Manufacturing Market reached USD 0.9 billion in 2022 and is expected to reach USD 3.8 billion by 2031 growing with a CAGR of 20.3% during the forecast period 2024-2031." As per DataM intelligence research report

Viral Vector Manufacturing Market growth opportunities(2025-2031):

The viral vector manufacturing market is entering a period of strong expansion, propelled by the dramatic rise in gene and cell therapy approvals and commercialization efforts. Continued surge in outsourcing to CDMOs, along with large-scale capacity build-outs, is driving infrastructure investment globally. Governments and venture capital are fueling R&D and facility launches, especially in North America, Europe, and Asia‐Pacific. Advances in automation, AI‐guided bioprocessing, and modular manufacturing platforms are enabling scalable, cost‐efficient production. Emerging economies with growing biotech capabilities and favorable policy reforms such as India and China offer untapped market access and localization opportunities.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/viral-vector-manufacturing-market?sp

Viral Vector Manufacturing Market: Recent Industry Developments

✅ In February 2025, Novartis inaugurated its first specialized viral vector production facility in Europe (VIFA One) in Mengeš, Slovenia, backed by a €40 million investment. The fully automated, robotics-enabled site boosts Novartis' capacity for manufacturing vectors for cell and gene therapies targeting cancer, genetic, and autoimmune diseases.

✅ In early 2025, the NSW Government committed AUD 134.5 million (approx USD 90 million) to establish a commercial viral vector facility at Westmead, Australia, with stage‐1 operations aimed at supporting clinical trials by 2025 and full-scale GMP capacity expected by end‐2024.

✅ In 2024-2025, SK Pharmteco expanded its viral vector platforms through acquisitions of Yposkesi and CBM, establishing a global footprint with multiple GMP facilities and developing AAVelocity and LentiSure platforms. The combined sites are set to reach ~800,000 sq ft by 2026, positioning SK as a top-tier CGT CDMO.

Viral Vector Manufacturing Market: Technological Advancements

✦ Modular, plug‐and‐play vector platforms enable CDMOs to tailor viral vectors across client programs while retaining core process consistency-reducing regulatory complexity and easing technology transfer.
✦ Closed and single‐use bioreactor systems with automation (including perfusion-style operation and in-line analytics) reduce contamination risk, improve throughput, and align with GMP standards.
✦ AI/ML‐driven process optimization is increasingly used to predict vector yields, tune cell line productivity, detect anomalies in real‐time, and simulate bioreactor performance via digital twins.
✦ AI‐guided capsid engineering for AAV applies machine learning to design novel capsids with enhanced tissue targeting, reduced immunogenicity, and higher transduction efficiency.
✦ Multi‐omics optimization of HEK293 production cell lines (genomic, proteomic, and metabolic profiling) has enabled higher rAAV yields and consistent product quality, bridging experimental knowledge into scalable manufacture.

Strategic Players Driving the Viral Vector Manufacturing Market Forward:

Sanofi SA, Thermo Fisher Scientific Inc., Cobra Biologics Ltd, Lonza Group Ltd, Merck & Co., Oxford BioMedica, CGT Catapult, UniQure NV, FUJIFILM Diosynth Biotechnologies, and Spark Therapeutics Inc.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/viral-vector-manufacturing-market?sp

Research Methodology:

The global Viral Vector Manufacturing Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Viral Vector Manufacturing Market:

➥By Type: Retroviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Other Viral Vectors
➥By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases
➥By Application: Gene Therapy, Vaccinology
➥By End User: Pharmaceutical and Biopharmaceutical Companies, Research Institutes

Regional Analysis for Viral Vector Manufacturing Market:

North America remains the powerhouse, accounting for a major share of global viral vector manufacturing revenue due to robust biotech infrastructure, regulatory support, and funding depth. Europe closely follows, leveraging strong CDMO presence and gene therapy pipelines. Asia‐Pacific is emerging as the highest-growth region, with rapid expansion of manufacturing facilities, government incentives, growing local R&D, and competitive production costs in countries like China and India.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=viral-vector-manufacturing-market?sp

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.